- Y Diweddaraf sydd Ar Gael (Diwygiedig)
- Gwreiddiol (a wnaed Fel)
The Veterinary Medicines Regulations 2013
You are here:
Pa Fersiwn
Nodweddion Uwch
- Dangos Graddfa Ddaearyddol(e.e. Lloegr, Cymru, Yr Alban aca Gogledd Iwerddon)
- Dangos Llinell Amser Newidiadau
Rhagor o Adnoddau
Status:
There are multiple versions of this provision on screen. These apply to different geographical extents.
Status
The term provision is used to describe a definable element in a piece of legislation that has legislative effect – such as a Part, Chapter or section.
Sometimes the text of a provision is changed, but the change(s) only apply to a particular geographical area. In some limited cases where this happens, the editorial team create a version for each different geographical area. Multiple versions are only created in this way where the change in question is a substitution so that there are different versions of the text for the different extents. Insertions and repeals of text do not give rise to such multiple versions.
Changes to legislation:
There are currently no known outstanding effects for the The Veterinary Medicines Regulations 2013, Paragraph 17.
Changes to Legislation
Revised legislation carried on this site may not be fully up to date. At the current time any known changes or effects made by subsequent legislation have been applied to the text of the legislation you are viewing by the editorial team. Please see ‘Frequently Asked Questions’ for details regarding the timescales for which new effects are identified and recorded on this site.
Application for a variation to a marketing authorisation F1....E+W+S
This
adran has no associated
Memorandwm Esboniadol
17.—(1) This paragraph applies in relation to an application for a variation to one or more marketing authorisations except where paragraph F2... 21 applies.
(2) The fees for the variations to which this paragraph applies are set out in the following table.
(3) Where applications are made at the same time seeking an identical change to the terms of more than one marketing authorisation, and those applications are based on identical data, fees are payable as for a grouped variation.
(4) References in this paragraph to a grouped variation being “led” by a particular type of variation indicate that the principal variation in that group is a variation of that type.
| [F3Type of variations | Fee (£) | ||
|---|---|---|---|
| Single variations; one change for each product | |||
| Variation – standard | 2,895 | ||
| Unless the variation is— | |||
| (a) a change of route of administration, or the addition of a new one, of— | |||
| (i) | an immunological product, or a pharmaceutical product for a non-food-producing animal | 5,390 | |
| (ii) | a pharmaceutical product for a food-producing animal | 7,135 | |
| (b) a change of bioavailability | 8,415 | ||
| (c) a change of active substance, where the change is to— | |||
| (i) | use a different biologically active substance with a slightly different molecular structure | 8,415 | |
| (ii) | modify the vector used to produce the antigen or the source material, including a new master cell bank from a different source | 8,415 | |
| (d) a change of pharmacokinetics | 8,415 | ||
| Simultaneous application falling within (a) to (d): fee for each additional product in the application | 1,465 | ||
| Variation – reduced | 885 | ||
| Variation - no assessment | 455 | ||
| Grouped variations | |||
| Variation – standard led | |||
| For the first nine changes | 6,280 | ||
| For each subsequent group of five or fewer changes | 2,250 | ||
| Variation – reduced led: | |||
| For the first nine changes | 1,770 | ||
| For each subsequent group of five or fewer changes | 2,250] | ||
Extent Information
E1This version of this provision extends to England and Wales and Scotland only; a separate version has been created for Northern Ireland only
Textual Amendments
F1Words in Sch. 7 para. 17 heading omitted (E.W.S.) (31.12.2020) by virtue of The Food and Drink, Veterinary Medicines and Residues (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/865), regs. 1(2), 17(4)(i); 2020 c. 1, Sch. 5 para. 1(1)
F2Words in Sch. 7 para. 17(1) omitted (E.W.S.) (17.5.2024) by virtue of The Veterinary Medicines (Amendment etc.) Regulations 2024 (S.I. 2024/567), regs. 1(1), 171(a)
F3Sch. 7 para. 17 Table substituted (E.W.S.) (17.5.2024) by The Veterinary Medicines (Amendment etc.) Regulations 2024 (S.I. 2024/567), regs. 1(1), 171(b)
Application for a variation to a marketing authorisation dealt with under national or mutual recognition variation procedures.N.I.
17.—(1) This paragraph applies in relation to an application for a variation to one or more marketing authorisations except where paragraph 18, 19 or 21 applies.
(2) The fees for the variations to which this paragraph applies are set out in the following table.
(3) Where applications are made at the same time seeking an identical change to the terms of more than one marketing authorisation, and those applications are based on identical data, fees are payable as for a grouped variation.
(4) References in this paragraph to a grouped variation being “led” by a particular type of variation indicate that the principal variation in that group is a variation of that type.
| Type of variation | National | UK is the reference member State | UK is a concerned member State | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Single variations; one change for each product | |||||||||
| Extension: | |||||||||
| Change of strength or potency or the addition of a new strength or potency: | 6,670 | - | 1,998 | ||||||
| Change of pharmaceutical form or the addition of a new pharmaceutical form: | 8,415 | - | 2,301 | ||||||
| Change of route of administration, or the addition of a new one, of— | - | ||||||||
| (i) an immunological product, or a pharmaceutical product for a [F4non-food-producing] animal: | 5,390 | - | 1,737 | ||||||
| (ii) a pharmaceutical product for a food-producing animal: | 7,135 | - | 2,058 | ||||||
| Change or addition of a food producing target species: | 9,620 | - | 2,547 | ||||||
| Change of active substance, including: | 8,415 | - | 2,301 | ||||||
| use of a different salt, ester, complex or derivative of the same therapeutic moiety: | |||||||||
| use of a different biologically active substance with a slightly different molecular structure: | |||||||||
| modification of the vector used to produce the antigen or the source material, including a new master cell bank from a different source: | |||||||||
| use of a new ligand or coupling mechanism for a radiopharmaceutical: | |||||||||
| change of the extraction solvent or change of the ratio of herbal drug to herbal drug preparation: | |||||||||
| Change of bioavailability: | 8,415 | - | 2,301 | ||||||
| Change of pharmacokinetics: | 8,415 | - | 2,301 | ||||||
| Simultaneous application: fee for each additional product in the application: | 2,895 | - | 1,011 | ||||||
| Type II: | 2,895 | 6,030 | 1,872 | ||||||
| Type IB: | 885 | 1,325 | 531 | ||||||
| Type IA: | 455 | 685 | 273 | ||||||
| Grouped variations | |||||||||
| Extension-led: | |||||||||
| The fee for an application for an extension-led grouped variation is the fee for that extension as specified above plus — | |||||||||
| (a) if there is one variation in addition to the extension, the fee for that variation as specified above; or | |||||||||
| (b) if there is more than one variation in addition to the extension, the fee that would be payable for a grouped variation of that type as specified below. | |||||||||
| Type II led: | |||||||||
| For the first nine changes: | 6,280 | 12,060 | 3,768 | ||||||
| For each subsequent group of up to ten changes: | 4,500 | 4,500 | 2,700 | ||||||
| Type IB led: | |||||||||
| For the first nine changes: | 1,770 | 2,650 | 1,062 | ||||||
| For each subsequent group of up to ten changes: | 4,500 | 4,500 | 2,700 | ||||||
| Type IA led: | |||||||||
| For the first nine changes: | 885 | 1,325 | 531 | ||||||
| For each subsequent group of up to ten changes: | 4,500 | 4,500 | 2,700 | ||||||
Extent Information
E2This version of this provision extends to Northern Ireland only; a separate version has been created for England and Wales and Scotland only
Textual Amendments
F4Words in Sch. 7 para. 17 substituted (14.4.2014) by The Veterinary Medicines (Amendment) Regulations 2014 (S.I. 2014/599), regs. 1, 4(2)
Options/Help
Print Options
PrintThe Whole Instrument
PrintThe Whole Schedule
PrintThe Whole Part
PrintThis Section only
You have chosen to open The Whole Instrument
The Whole Instrument you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
You have chosen to open The Whole Instrument as a PDF
The Whole Instrument you have selected contains over 200 provisions and might take some time to download.
Would you like to continue?
You have chosen to open yr Offeryn Cyfan
Yr Offeryn Cyfan you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
You have chosen to open Schedules only
Y Rhestrau you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
Mae deddfwriaeth ar gael mewn fersiynau gwahanol:
Y Diweddaraf sydd Ar Gael (diwygiedig):Y fersiwn ddiweddaraf sydd ar gael o’r ddeddfwriaeth yn cynnwys newidiadau a wnaed gan ddeddfwriaeth ddilynol ac wedi eu gweithredu gan ein tîm golygyddol. Gellir gweld y newidiadau nad ydym wedi eu gweithredu i’r testun eto yn yr ardal ‘Newidiadau i Ddeddfwriaeth’.
Gwreiddiol (Fel y’i Deddfwyd neu y’i Gwnaed): Mae'r wreiddiol fersiwn y ddeddfwriaeth fel ag yr oedd pan gafodd ei deddfu neu eu gwneud. Ni wnaed unrhyw newidiadau i’r testun.
Gweler y wybodaeth ychwanegol ochr yn ochr â’r cynnwys
Rhychwant ddaearyddol: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.
Dangos Llinell Amser Newidiadau: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.
Dewisiadau Agor
Dewisiadau gwahanol i agor deddfwriaeth er mwyn gweld rhagor o gynnwys ar y sgrin ar yr un pryd
Memorandwm Esboniadol
Mae Memoranda Esboniadol yn nodi datganiad byr o ddiben Offeryn Statudol ac yn rhoi gwybodaeth am ei amcan polisi a goblygiadau polisi. Maent yn ceisio gwneud yr Offeryn Statudol yn hygyrch i ddarllenwyr nad oes ganddynt gymhwyster cyfreithiol, ac maent yn cyd-fynd ag unrhyw Offeryn Statudol neu Offeryn Statudol Drafft a gyflwynwyd ger bron y Senedd o Fehefin 2004 ymlaen.
Rhagor o Adnoddau
Gallwch wneud defnydd o ddogfennau atodol hanfodol a gwybodaeth ar gyfer yr eitem ddeddfwriaeth o’r tab hwn. Yn ddibynnol ar yr eitem ddeddfwriaeth sydd i’w gweld, gallai hyn gynnwys:
- y PDF print gwreiddiol y fel deddfwyd fersiwn a ddefnyddiwyd am y copi print
- rhestr o newidiadau a wnaed gan a/neu yn effeithio ar yr eitem hon o ddeddfwriaeth
- manylion rhoi grym a newid cyffredinol
- pob fformat o’r holl ddogfennau cysylltiedig
- slipiau cywiro
- dolenni i ddeddfwriaeth gysylltiedig ac adnoddau gwybodaeth eraill
Asesiadau Effaith
Impact Assessments generally accompany all UK Government interventions of a regulatory nature that affect the private sector, civil society organisations and public services. They apply regardless of whether the regulation originates from a domestic or international source and can accompany primary (Acts etc) and secondary legislation (SIs). An Impact Assessment allows those with an interest in the policy area to understand:
- Why the government is proposing to intervene;
- The main options the government is considering, and which one is preferred;
- How and to what extent new policies may impact on them; and,
- The estimated costs and benefits of proposed measures.
Llinell Amser Newidiadau
This timeline shows the different points in time where a change occurred. The dates will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. The first date in the timeline will usually be the earliest date when the provision came into force. In some cases the first date is 01/02/1991 (or for Northern Ireland legislation 01/01/2006). This date is our basedate. No versions before this date are available. For further information see the Editorial Practice Guide and Glossary under Help.
Rhagor o Adnoddau
Defnyddiwch y ddewislen hon i agor dogfennau hanfodol sy’n cyd-fynd â’r ddeddfwriaeth a gwybodaeth am yr eitem hon o ddeddfwriaeth. Gan ddibynnu ar yr eitem o ddeddfwriaeth sy’n cael ei gweld gall hyn gynnwys:
- y PDF print gwreiddiol y fel gwnaed fersiwn a ddefnyddiwyd am y copi print
- slipiau cywiro
liciwch ‘Gweld Mwy’ neu ddewis ‘Rhagor o Adnoddau’ am wybodaeth ychwanegol gan gynnwys
- rhestr o newidiadau a wnaed gan a/neu yn effeithio ar yr eitem hon o ddeddfwriaeth
- manylion rhoi grym a newid cyffredinol
- pob fformat o’r holl ddogfennau cysylltiedig
- dolenni i ddeddfwriaeth gysylltiedig ac adnoddau gwybodaeth eraill
Mae’r holl gynnwys ar gael dan Drwydded Llywodraeth Agored v3.0 ac eithrio ble nodir yn wahanol. Yn ychwanegol mae’r safle hwn â chynnwys sy’n deillio o EUR-Lex, a ailddefnyddiwyd dan delerau Penderfyniad y Comisiwn 2011/833/EU ar ailddefnyddio dogfennau o sefydliadau’r UE. Am ragor o wybodaeth gweler ddatganiad cyhoeddus Swyddfa Gyhoeddiadau’r UE ar ailddefnyddio.